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Abstract
Homogeneous ultralow-dose (30 mg) tablets were prepared from perfectly free-flowing granules manufactured by continuous 
Twin-Screw Wet Granulation. The gravimetrically fed mixture of lactose and potato starch of low particle size was successfully 
agglomerated and the size enlargement technology proved to be very robust. Since the incorporated drug was dissolved in ethanol-
based granulation liquid, the resulting homogeneity largely depended on the dosing of the applied liquid administering units. 
A peristaltic pump generated higher deviation of the drug content in tablets (Relative Standard Deviation (RSD): 7.7 %) compared to a 
syringe pump (RSD: 2.3 %) or a piston pump (RSD: 4.6 %). This is due to the pulsation of the liquid flow generated by the peristaltic 
pump according to the real-time measured mass of the fed liquid. A good correlation was found between the RSD of the liquid 
mass flow (calculated from the recorded masses) and the RSD of the drug content. Based on the results, the goodness of Content 
Uniformity, as the most relevant critical quality attribute of low-dose products, was determined by the characteristics of the applied 
dosing units. The feeding characteristic of the different pumps could be easily measured by the introduced balance-based method 
and therefore, the applicability of the pumps could be evaluated.
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1 Introduction
Granulation is one of the most commonly used technol-
ogy in the pharmaceutical industry [1]. Its significance 
stems from the ability to produce enlarged particle sizes 
(granules) possessing superior downstream proper-
ties [2]. These include improved flowability, bulk density 
and compaction characteristics coupled with increased 
resistance to segregation ensuring reproducible tableting 
with exceptional quality [3].
Compared to the two conventional wet granulation 
methods (fluid bed and high-shear granulation), Twin-
Screw Wet Granulation (TSWG) definitely needs to be 
considered unique [4, 5]. TSWG can be operated continu-
ously granting numerous advantages over other traditional 
batch methods [6] such as easier scale-up, more uniform 
product quality, better controllability, etc. Since contin-
uous technologies are heavily promoted by the authori-
ties [7, 8], intense R&D efforts are going into their possi-
ble industrial applications [9, 10]. Numerous papers have 
been published based on the research conducted on Twin-
Screw Granulators [11–17].
The influence of some processing parameters (such as 
liquid-to-solid ratio, screw speed, input rate, screw con-
figuration, barrel fill level, etc.) in course of TSWG has 
been thoroughly investigated from the start of the ascen-
sion of this technology [18–23]. The overall success evalu-
ations of these studies are generally based on the reported 
granule properties (Particle Size Distribution (PSD), 
compressibility, friability, etc.) and consequent tablet 
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characteristics (hardness, friability, time of disintegra-
tion, etc.). Interestingly, the evaluation of liquid distri-
bution in the granulator is usually excluded from these 
investigations despite it undoubtedly has a significant 
impact on the resulting granule properties, especially 
on the PSD. According to El Hagrasy et al. [24], granules 
obtained by TSWG usually have bimodal size distribution 
due to the poor liquid distribution. This phenomenon was 
also observed by Dhenge et al. [25], although by apply-
ing a binder with a sufficiently high viscosity, the coveted 
mono-modal PSD was achieved. Yu et al. [26] showed 
that increasing hydrophobicity led to a more heteroge-
neous liquid distribution resulting in a relatively large 
portion of fines. Liquid distribution can also be examined 
by adopting a tracer method as demonstrated by a few 
papers in the literature [27–31]. Consequently, the under-
standing of the liquid distribution phenomenon during 
TSWG is crucial, and real-time monitoring techniques 
such as near-infrared chemical imaging can become 
a valuable tool in the future [32]. In special cases, such as 
when the API and the binder are co-dissolved in the gran-
ulating liquid, the requirement of a homogeneous liquid 
distribution can be even more pronounced.
Generally, a TSWG setup consists of two intermesh-
ing, co-rotating screws placed in a barrel. The screws are 
made up of Conveying Elements, comb mixer elements 
and kneading blocks. These generate different levels of 
shear force on the materials enabling proper mixing and 
granulation of the powder mixture [33]. However, in order 
to achieve the desired granule properties, the performance 
of the feeding system needs to be consistent [24, 34]. 
Taking a regular Twin-Screw Granulation into consider-
ation, at least one powder feeder and a liquid dosing unit 
are necessary to proceed with operations. Powder feed-
ing can be challenging when the API is applied in micron-
ized form possessing poor flow characteristics or charge 
electrostatically [35]. In terms of liquid or drug solution 
dosing, the regularly adopted peristaltic pumps may show 
pulsating flow profiles leading to undesirable granule 
properties [36, 37] or even API homogeneity issues if it is 
dissolved in the liquid. To produce low-dose tablets con-
taining granules prepared by TSWG liquid dosing might 
be one of the most Critical Process Parameters.
In the case of low-dose (API content is below 2 % [38]) 
drug products, pharmaceutical companies mostly choose 
wet granulation in order to meet the strict Content 
Uniformity requirements set by the authorities [39]. 
However, these are dominantly batch technologies that do 
not possess the advantages and conveniences of the afore-
mentioned continuous ones. Only one publication men-
tions that a tracer molecule (riboflavin sodium phosphate 
dissolved in liquid) could be homogeneously distributed 
in granules after TSWG, however, the homogeneity stud-
ies were not extended to tablets [19]. Consequently, the 
main objective of this work was to produce novel homoge-
neous ultralow-dose tablet batches based on a continuous 
TSWG technology. In order to achieve this challenging 
task, the following subgoals were set:
• develop a technology consisting of TSWG, fluid-bed 
drying, sieving, and tableting generating ultralow-
dose tablets with adequate Content Uniformity being 
the most important Critical Quality Attribute (CQA);
• examine the impact of different pumps as Critical 
Process Parameters (CPP) on API homogeneity and 
characterize them in terms of variability of the liquid 
addition rate by real-time mass measurements;
• compare the outcome of the obtained Content 
Uniformities to the results of the balance-based pump 
characterization in order to evaluate the applicability 
of certain dosing units from a CQA standpoint.
During the experimental work, a poorly flowable mix-
ture (ideal for granulation) of α-lactose monohydrate and 
potato starch was granulated with polyvinylpyrrolidone 
K30. For the non-placebo experiments, carvedilol (CAR), 
a non-selective ß-blocking agent, was chosen as model 
API (the drug was selected for analytical reasons, not 
for any biological relevance at such a low concentration). 
According to the authors' best knowledge, this is the first 
time when tablets consisting of an API with an extremely 
low dose (30 µg) was developed through a continuous 
TSWG technology. Ethanol was selected as the granulating 
liquid since it dissolves the API easily as opposed to water. 
Pumps with different working principles (peristaltic, pis-
ton and syringe pump) have been compared in terms of 
ability to generate granules with homogeneous API con-
tent. By applying carvedilol in the liquid phase, the result-
ing homogeneity will mainly depend on the adopted dos-
ing units and the necessity of blend uniformity justification 
in the lactose-starch-API mixture could be avoided.
2 Materials and methods
2.1 Materials
Carvedilol (CAR) with a purity of ≥ 98 % and a melting 
point of 117 °C along with 96 % ethanol and methanol 
were provided by Sigma-Aldrich (Budapest, Hungary). 
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Fine α-lactose monohydrate (GranuLac® 230 mesh) was 
supplied by Meggle Pharma (Wasserburg, Germany), 
Kollidon® 30 (Povidone, PVPK30) was shipped by BASF 
(Ludwigshafen, Germany) and potato starch was pro-
vided by Roquette Pharma (Lestrem, France). For tablet-
ing, Aerosil® 200 (fumed silica) was supplied by Evonik 
Industries (Essen, Germany), while stearic acid and mag-
nesium-stearate were given by Hungaropharma Ltd. 
(Budapest, Hungary).
2.2 Granule production
Granulation experiments were conducted in a multifunc-
tional continuous twin-screw equipment (TS16, Quick 
2000 Ltd, Hungary) operated in wet granulation mode 
with a basic screw speed of 150 rpm (revolutions per min-
ute), a screw diameter of 16 mm (25 L/D ratio), and a set 
configuration shown in Fig. 1 (CE: Conveying Elements, 
KZ: Kneading Zones). The Kneading Zones consisted 
of individual elements set up in a 45° angle with a for-
ward configuration (first zone 5 elements; second zone: 
15 elements; third zone: 10 elements). Elements before 
the Kneading Zones were Conveying Elements with small 
pitch size to accumulate enough materials for the granula-
tion. Elements after the Kneading Zones were Conveying 
Elements with large pitch size to facilitate the transport of 
the granules. The TSG was operated at room temperature, 
without applying any additional heating.
A gravimetric feeder (type: DDW-MD0-MT HYD ISC 
plus, Brabender Technologie, Duisburg, Germany) was 
adopted in order to dispense the solid blend of lactose and 
starch into the Twin-Screw Granulator (TSG) with apply-
ing a constant feeding rate of 1 kg/h. These pre-blends 
were carried out manually in plastic bags within a duration 
of 5 minutes. The granulation liquid (PVPK30 and CAR 
were dissolved in ethanol) was dosed into the second zone 
of the device using a peristaltic pump (Watson-Marlow 
120U, Wilmington, MA, USA) or a syringe pump (SEP-
10S Plus, Aitecs, Vilnius, Lithuania) or a piston pump 
(JASCO PU-980, Hachioji, Japan) with a constant feed 
rate of 165 ml/h (in case of the peristaltic pump, the feed-
ing speed was set based on a previously made calibration). 
In each case, the liquid was fed through a silicone tube 
with an inner diameter of 3.1 mm. The peristaltic pump 
was applied for the placebo experiments.
The prepared wet granules were then subsequently dried 
in a lab-scale fluid bed dryer (Aeromatic Strea-1, Düsseldorf, 
Germany) with a drying temperature of 50 °C in 5 minutes, 
and lastly passed through a 0.8 mm hand sieve.
2.3 Granule characterization
The residual moisture contents of the dried granules were 
determined by a moisture analyzer (Sartorius MA 40, 
Göttingen, Germany). In each case, granules with an approx-
imate weight of 2 grams were evaluated (105 °C, 3 min).
The Particle Size Distribution (PSD) measurements 
were measured by a Malvern Mastersizer 2000 laser dif-
fraction device (Malvern Pananalytical, Malvern, UK) 
in solid state. The dispersive air pressure was set to 1 bar.
Bulk and tapped density measurements were carried 
out according to the USP [40] by adopting an SVM 12 
tapped density tester (ERWEKA GmbH, Heusenstamm, 
Germany). A total granule weight of 100 grams was eval-
uated accordingly. For tapped density measurements, 
the number of taps was set to 1200.
Granule flowability measurements were carried out 
with a funnel described in ASTM D 1895 and ISO R60 (ori-
fice was 10 mm wide). The time necessary for 100 grams 
of granule to flow out of the funnel was measured by a 
stopwatch. The experiments were done in triplicates.
2.4 Tableting and physical tablet tests
Prior to compaction, the final powder mixture was pre-
pared through simple homogenization steps. The gran-
ules were blended with the components of the outer phase 
in plastic bags according to the following chronological 
order: glidant (1 min), stearic acid (30 sec) and lastly mag-
nesium stearate (30 sec). The powder mixtures were com-
pressed into tablets on a Piccola tablet rotary press (Riva, 
Aldershot, UK) equipped with concave punches of 6 mm 
diameter and no markings. Turret speed was 40 rpm, Fill-
O-Matic was 15 rpm and main compression force was 
between 4 and 10 kN.
Batch characteristics are detailed in Table 1. (Due to 
confidential reasons, the quantitative composition could 
not be disclosed.)
The compressed tablets were evaluated by standard 
tests such as tablet weight, thickness, hardness, friabil-
ity measurements and time of disintegration. Most of 
these physical parameters were determined by an Erweka Fig. 1 The adopted screw configuration of the Twin-Screw Granulator
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MultiCheck apparatus, while friability tests were con-
ducted in a Pharmatest PTFR-A analyzer and disintegra-
tion time was measured in a Pharmatest PTZ-Auto disinte-
gration tester in water (37±0.5 °C). In total, 10 tablets were 
examined by the MultiCheck, 6 tablets were studied by the 
PTZ-Auto and tablets with the sum weight of 6.5 grams 
were evaluated by the PTFR-A. Friability tests were made 
according to the USP with 100 turns in 4 min [41].
2.5 Content Uniformity (CU) analysis
CU was determined by High-Performance Liquid 
Chromatography (HPLC). Ten randomly chosen tablets 
were individually placed into 10 mL volumetric flasks 
where they were disintegrated in a mixture of metha-
nol and purified water (1:1) within an ultrasonic bath 
in 15 min. Upon completion, the suspensions were filtered 
by a 0.45 µm polytetrafluoroethylene (PTFE) syringe fil-
ter. The examinations were carried out on a reversed-phase 
HPLC column (Agilent 1200 series LC system, Santa Clara, 
CA, USA) with a gradient elution of 0.1 M phosphoric acid 
and acetonitrile at 25 °C (flow rate was set to 1.0 ml/min). 
The concentration of CAR was determined based on the 
UV absorption of the injected solution at 285 nm.
2.6 Measurement of the liquid addition rate of 
different pumps
In these experiments, the granulating liquid (ethanolic solu-
tion of PVPK30) was fed from a bottle to a plastic glass 
by using the aforementioned pumps and tubes. The plastic 
glass was placed on a Sartorius MC-1 AC 210 P analytical 
balance (Göttingen, Germany) connected to a laptop. On the 
laptop, an in-house built software was run, which received 
the mass recorded on the balance in real-time (the data was 
automatically written into a text file). The mass of the liquid 
was recorded every 0.2 seconds. The mass flow was calcu-
lated based on the masses recorded 5 seconds separately.
3 Results and discussion
As it was shortly summarized in the introduction, our goal 
was to produce low-dose API-containing, highly homoge-
neous tablets compressed from continuously manufactured 
granules fabricated by a TSWG technology. However, 
before the actual experiments with CAR began, placebo 
batches were produced in order to evaluate the quality of 
the granules (and later tablets). The manufactured granules 
were examined thoroughly (PSD, granulometry, residual 
moisture content) followed by compression into tablets. 
Once these preliminary tests were concluded, the exper-
iments with CAR could be performed.
3.1 Placebo results
3.1.1 Granule production
As it was mentioned in the introduction part, the effect of 
parameter changing during continuous TSWG is a highly 
examined subject in the literature. Therefore, it was not 
included in our goals to cover this topic. The parameter 
settings of the performed experiments are summarized 
in Table 2.
During the initial experiment, the PVP was dissolved 
in ethanol to form the granulating liquid to be dosed 
into the second zone of the continuous TSG equipment. 
In the next (downstream) step, the applicability of wet 
sieving was compared to the results of standard dry siev-
ing. This experiment was deemed necessary in order 
to determine its effect on the consequent granule PSD. 
The final trial, when the PVP was pre-blended with lac-
tose and starch to form a premix, is considered nota-
ble from the aspect of industrial adaptability of TSWG. 
By simply homogenizing the binder with the other excip-
ients, the time needed to prepare the granulation liq-
uid (pure solvent) was greatly reduced. Ultimately, this 
method decreases the complexity of the granulation. 
However, it is unknown if it will change the granulation 
mechanism and/or impair the PSD.
Upon completion, the wet granules were dried in a 
fluid bed dryer. During this operation, it is necessary 
to keep the product temperature at a reasonably low level 
to protect the future batches (that will incorporate API) 
from potential degradation.
Table 1 Batch characteristics
Applied 
API
API dose 
(µg)
Tablet weight 
(mg)
Batch size 
(tablets)
Total weight 
(g)
Carvedilol 30 85 6000 510
Table 2 TSWG settings of the placebo granulations
Settings
PVP 
quantity 
(%)
Screw 
speed 
(rpm)
Binder 
addition
Drying 
(°C, min)
Sieving 
(before or 
after drying)
Dissolved 
PVP
3 150 Solution 50;5 After
PVP 
premix 3 150 Premix 50;5 After
Wet 
sieving 3 150 Solution 50;5 Before
Démuth et al.
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3.1.2 Granule characterization
The continuously manufactured placebo granules were 
examined and evaluated by PSD, flowability, residual mois-
ture content and lastly bulk and tapped density measure-
ments. The results along with the correspondent data of 
the starting lactose-starch mixture are detailed in Table 3.
Based on the density values, the compressibility indices 
and Hausner ratios were also determined. These non-in-
trinsic powder properties are easily calculated and provide 
valuable information regarding flow characteristics [42]. 
According to the results, each experiment produced 
highly flowable granules, confirmed not only by the cal-
culated values but by the highly successful funnel flow-
ability tests (10–12 s/100 g). In comparison, the starting 
lactose-starch powder mixture could not pass through the 
orifice. Interestingly, the product made by wet sieving 
exhibited good flow properties in spite of the significantly 
lower particle size (and less advantageous PSD, see Fig. 2).
The moisture content results demonstrate that none 
of the manufactured batches contained more than 4 % 
of moisture. The received values enabled the consequent 
tableting process to be carried out easily. No signs of cap-
ping, lamination (a possible cause of low moisture con-
tent) and sticking (a possible cause of high moisture con-
tent) were observed throughout the operation. Wet sieving, 
since smaller particles were dried, facilitated the evapora-
tion of ethanol, thus by applying the same drying method, 
lower residual moisture content was achieved (3.19 %).
Out of all granule characterization methods, PSD mea-
surements and their evaluations can be considered as the 
most vital and important [43], since it provides direct feed-
back on the actual success or failure of the size enlarge-
ment process. Prior to granulation, the desired range was 
determined to be between 90 and 1000 µm following 
sieving with a unimodal distribution. At this range, gran-
ules generally possess the necessary attributes needed 
for the upcoming manufacturing stages [44]. The results 
of the PSD measurements are shown in Fig. 2.
Based on the PSD results of the starting materials (lac-
tose, starch), their small average particle size is clearly 
apparent. The d(0.9) values of lactose and starch were found 
to be 57 and 79 microns making their possible future appli-
cation without granulation impossible. Contrarily, the PSDs 
of the granulated samples were more favorable as the prod-
ucts had d(0.9) values in the upper hundred-micron range. 
These results demonstrate the applicability of this contin-
uous TSWG technology for size enlargement purposes. 
Granulation carried out with the initial dissolved PVP set-
tings produced high-quality granules with a unimodal dis-
tribution profile [24]. The premixing of PVP caused a slight 
increase of fines indicating that the binder was unable 
to blend perfectly with the excipients resulting in an incom-
plete granulation, although the final result was still deemed 
acceptable (majority of the granules belonged to the desired 
90–1000 µm range and the d(0.9) value remained above 
800 µm). The implementation of wet sieving produced great 
amounts of fines suggesting that the bonds constructed by the 
binder between the excipient particles can be broken before 
the subsequent drying step could solidify them. Based on 
Table 3 The measured characteristics of the starting powder mixture and the granules
Characteristics Bulk density 
(g/cm3)
Tapped density 
(g/cm3)
Compressibility 
index (%)
Hausner ratio
Flowability 
(s/100 g)
d(0.9) (µm) Residual 
moisture (%)
Lactose-starch 
premix 0.488 0.677 27.92 1.39 Non-flowing
Lactose: 57
Starch: 79
3.34
Dissolved PVP 0.576 0.640 10.00 1.11 10.75±0.06 1084 3.98
PVP premix 0.550 0.625 12.00 1.14 11.01±0.52 831 3.61
Wet sieving 0.499 0.559 10.73 1.12 12.05±0.21 506 3.19
Fig. 2 Particle Size Distribution results based on laser diffraction 
measurements following sieving (0.8 mm)
6|Démuth et al.Period. Polytech. Chem. Eng. 
this outcome, the potential application of wet sieving in the 
upcoming API experiments was discarded. The granulation 
with the placebo system was deemed successful, and the 
obtained granules were appropriate. Therefore, no further 
optimization of TSWG seemed necessary.
3.1.3 Tableting
Two of the discussed three kinds of granules were cho-
sen to be compressed into tablets for further investigation. 
The batches manufactured with the dissolved PVP and 
the PVP premix were selected and processed accordingly. 
These two samples were chosen since the mechanism of 
the granulation (the binding bridge formation among the 
particles) might be different, which can have a significant 
impact on the resulting tablet properties. Upon comple-
tion of the final powder mixtures, the blends were com-
pressed into tablets and their characteristics were mea-
sured and evaluated.
The results are detailed in Table 4. According to the 
results, the batches containing PVP in premix produced 
slightly stronger tablets with the same compression force, 
while the average time of disintegration was approxi-
mately identical. In each case, the disintegration limit 
of 30 minutes set by the Pharmacopeia [45] was easily 
achieved (2–3 minutes). Average tablet hardness values 
were ranging from 75 to 143 N, monotonically increasing 
with compression force but reaching a close to the max-
imum value already at 8 kN (dissolved PVP) and 6 kN 
(PVP premix). Tablets produced with the dissolved binder 
had significantly lower friability at all compression forces, 
which can be attributed to the enhanced binding ability of 
PVP in a solution, but the possibility of reaching the max-
imum limit of 1 % was never at risk. Based on the obtained 
results of the placebo system, the granulation method 
with dissolved PVP in the granulation liquid was chosen 
for the experiments with the active ingredient.
3.2 The results of CAR tablets
3.2.1 Content Uniformity of CAR tablets
As it was briefly mentioned in the introduction, meeting 
the Content Uniformity criteria in low-dose drug products 
can be very challenging [46]. High standard deviation of 
the incorporated drug can particularly be characteristic 
of low-dose formulations. Studies conducted on this field 
based on continuous TSWG are very limited. In order to 
obtain highly homogeneous tablet batches, CAR was dis-
solved in the granulating liquid, since the accurate dosing 
of the API with a continuous powder feeder at such a low 
concentration (0.035 w/w%) can make the homogenization 
even more challenging.
In accordance with the preliminary placebo tab-
let results, the initial dissolved PVP settings were cho-
sen to produce the CAR-containing batches based on the 
TSWG technology. Since the API content is extremely 
low, its potentially unfavorable effect on the success of 
granulation was deemed negligible. Finding the most 
Critical Process Parameter affecting homogeneity can be 
a cornerstone of this technology. As CAR was dissolved 
in the ethanol, it seemed worthy to investigate the liquid 
dispensing unit, especially the applied pump. Throughout 
these experiments, three pumps with different work-
ing principles (peristaltic pump, syringe pump, piston 
pump) were adopted in order to reveal whether the type 
of the employed pump has any significant effect on the 
outcome of success in CAR homogeneity. Drug content of 
the final dosage forms was measured and their RSD was 
subsequently calculated. These are summarized in Fig. 3.
According to the results, the application of the peristal-
tic pump produced larger RSD values in the tablets indicat-
ing a highly inhomogeneous batch. The apparent pulsating 
flow observed throughout the operation of the peristal-
tic pump ultimately leads to inconsistent feeding, which 
prevents the low-dose API to evenly blend with the other 
Table 4 Physical test results of the placebo tablets compressed from granules manufactured by TSWG
Compression force (kN) 4 6 8 10 4 6 8 10
Granule production method Dissolved 
PVP
Dissolved 
PVP
Dissolved 
PVP
Dissolved 
PVP
PVP premix PVP premix PVP premix PVP premix
Weight (mg) 83.4±0.6 83.9±0.7 83.9±0.7 83.4±0.8 86.7±0.8 88.4±0.4 84.0±0.4 83.8±0.5
Thickness (mm) 2.58±0.01 2.53±0.01 2.48±0.01 2.45±0.02 2.64±0.03 2.61±0.01 2.47±0.01 2.45±0.02
Diameter (mm) 5.96±0.01 5.96±0.01 5.96±0.01 5.98±0.02 5.97±0.01 5.97±0.01 5.96±0.01 5.99±0.02
Hardness (N) 75±7 101±13 134±13 136±10 87±10 127±12 134±9 143±5
Friability (%) 0.248 0.282 0.26 0.292 0.360 0.352 0.324 0.415
Disintegration (s) 115±43 131±39 164±32 196±64 126±32 129±45 168±30 119±75
Démuth et al.
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materials. As opposed to the peristaltic pump, syringe 
and piston pump ensured lower RSDs of the CAR con-
tent. The best result was achieved by applying the syringe 
pump. It seems obvious that the type of pump has a sig-
nificant effect on the homogeneity of the API. It can be 
claimed that when the API is dissolved in the granulating 
liquid, the successful result of the most important CQA 
(Content Uniformity) of low-dose products can be linked 
to the liquid dosing rate (and thus, the type of the pump) 
as the most important correspondent CPP. Defining CPPs 
and CQAs in pharmaceutical development are an integral 
part of the Quality by Design (QbD) guidelines promoted 
by the Food and Drug Administration [47].
3.2.2 Pump characteristics – the dosing profiles
As the liquid dosing rate was proved to be a critical param-
eter, it is worth to put effort into determining it with a sim-
ple method (that ultimately could be used as an in-line soft 
sensor too) as suggested by the QbD guidelines.
In order to compare the different pumps, the liquid addi-
tion rate of the three applied types was measured as indi-
cated in Section 2.6. The recorded rate for one minute 
in case of each pump is shown in Fig. 4. The tested aver-
age feeding speeds were realistic, similar to one applied 
during normal granulation runs.
Not surprisingly, the least consistent feeding was pro-
vided by the peristaltic pump showing a sinusoidal profile 
(RSD of the mass flow: 10 %). With the piston pump, more 
consistent dosing of the ethanolic solution was achieved 
(RSD: 5.6 %). A very steady dispensing of the liquid 
was realizable with the syringe pump (RSD: 3.4 %). 
Therefore, the application of the latter two pumps is rec-
ommended when homogeneity of the liquid (and possibly, 
the dissolved drug) is of great importance. The inconsis-
tent feeding of the granulating liquid may lead to more 
disadvantageous PSDs [12] (besides the inhomogeneous 
drug distribution) especially if the granulating agent is 
dissolved in it.
If the RSD values of the mass flows belonging to the dif-
ferent pumps are compared to the RSD values of the drug 
content in tablets, a good correlation can be found (Fig. 5).
The linear correlation means that based on the mea-
surement of the liquid flow rate (as CPP), the Content 
Uniformity (as CQA) can be estimated in this case. 
Looking into the applicability of this system is the contin-
uation of this work.
Based on these profiles produced through simple tests, 
the adaptability of certain pumps in future granulation 
experiments could be determined. Additionally, only min-
imal amounts of material – even without an API – is nec-
essary to carry out these investigations. By the upcoming 
development of a residence time distribution model (based 
on a former approach [48]), an even more precise method 
will be established to estimate Content Uniformity and 
Fig. 3 Relative Standard Deviation of the CAR content in tablets 
(granules were made with different pumps)
Fig. 4 Liquid dosing rates of (a) peristaltic pump (b) piston pump 
(c) syringe pump (red lines denotes the average mass flow values 
while the dashed lines mark the ±5 % deviation
Fig. 5 Correlation between RSD values of mass flows and of 
CAR content
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to determine which profiles are acceptable and which are 
not for certain purposes. Ultimately, this will be the "digi-
tal twin" of the continuous TSWG unit.
4 Conclusion
Placebo tablet batch productions based on continu-
ous Twin-Screw Wet Granulation proved to be a robust 
technology resulting in excellent physical properties. 
This developed system served as a foundation for the 
investigation on how to manufacture highly homogeneous 
low-dose tablets by a continuous granulating platform.
This work demonstrates the inaugural preparation of 
homogeneous ultralow-dose tablet batches based on a con-
tinuous Twin-Screw Wet Granulation technology. With the 
binder and the API dissolved in the granulating liquid, pump 
characteristic (i.e. the liquid dosing rate) was determined 
as the most important Critical Process Parameter (CPP) 
in terms of acceptable homogeneity and consequent Content 
Uniformity (CQA). The feeding characteristic of the dif-
ferent pumps could be determined easily by the introduced 
simple balance-based method and this novel approach can 
be applied for following the granulation process as an in-line 
process analytical solution. Pumps showing no pulsation of 
the fed liquid (syringe pump, piston pump) can produce gran-
ules with more homogeneous drug distribution compared 
to regularly applied peristaltic pumps. The peristaltic pump 
was shown to feed the liquid sinusoidally, which causes 
an inhomogeneous distribution of the API. Consequently, 
in the case of low-dose drug development with continuous 
Twin-Screw Granulation based on dissolving the API(s) 
in the granulating liquid, the application of a pulse-free dos-
ing pump is of great importance.
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